TIDMC4XD

RNS Number : 9517V

C4X Discovery Holdings PLC

07 December 2023

C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company")

Notice of Results

7 December 2023 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, will be announcing its full year results for the year ended ended 31 July 2023 on Thursday 14 December 2023.

- ENDS -

For further information, please contact:

 
 C4X Discovery Holdings 
 Mo Noonan, Communications                    +44 (0)787 6444977 
 
 Panmure Gordon (UK) Limited (NOMAD and 
  Broker) 
 Freddy Crossley, Emma Earl (Corporate 
  Finance)                                    +44 (0)20 7886 2500 
 Rupert Dearden (Corporate Broking) 
 
 C4X Discovery Media - ICR Consilium 
 Mary-Jane Elliott, Chris Gardner, Matthew 
  Neal                                        +44 (0)203 709 5700

Notes to Editors:

About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world leading medicines, which are developed by our partners for the benefit of patients. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, oncology, neurodegeneration and addictive disorders. Our commercially attractive portfolio ranges from early-stage novel target opportunities to late-stage Drug Discovery programmes ready for out-licensing to partners and we have two commercially partnered programmes with one candidate in clinical development.

We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development. Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORTFBMTMTBMTJJ

(END) Dow Jones Newswires

December 07, 2023 02:00 ET (07:00 GMT)

C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more C4x Discovery Charts.
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more C4x Discovery Charts.